Handelsavisen
prelaunch
Companies Healthcare FLUO.ST
FL
FLUO.ST Nasdaq Stockholm Advanced Medical Equipment & Technology

Fluoguide AS

kr30,80
Open in Charts → Attach watcher ⌖
SEK
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
0,00 %
Op margin
ROE
-127,9 %
Net margin
Debt / equity
1,81
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Fluoguide AS develops and commercializes advanced medical equipment and technology, primarily focused on diagnostic and therapeutic solutions in the healthcare sector.

Business. Fluoguide AS (FLUO.ST) is a healthcare company specializing in advanced medical equipment and technology. The firm operates within the Healthcare Services & Equipment industry, focusing on the development and sale of medical devices. Headquartered in Norway, the company is primarily listed on the Nasdaq Stockholm exchange. Specific details regarding operating segments and geographic revenue mix are not disclosed in the available data.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryAdvanced Medical Equipment & Technology
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
-127,9 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning FLUO.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to FLUO.ST. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Fluoguide AS (FLUO.ST) is a healthcare company specializing in advanced medical equipment and technology. The firm operates within the Healthcare Services & Equipment industry, focusing on the development and sale of medical devices. Headquartered in Norway, the company is primarily listed on the Nasdaq Stockholm exchange. Specific details regarding operating segments and geographic revenue mix are not disclosed in the available data.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryAdvanced Medical Equipment & Technology
    AI synthesis
    GENERATED

    Fluoguide's capital structure is characterized by a debt-to-equity ratio of 1.81, indicating a relatively high leverage position. The company's liquidity is assessed as medium, with a current ratio of 1.31, suggesting it has sufficient short-term assets to cover its short-term liabilities, but with limited buffer. The company reported negative operating and free cash flows of -10.67 million DKK and -8.19 million DKK, respectively, indicating ongoing cash burn.

    Profitability metrics are negative, with a return on equity of -127.89% and a return on assets of -36.48%, both significantly below the industry median for advanced medical equipment and technology firms. The company's operating income and net income were -8.35 million DKK and -7.52 million DKK, respectively, reflecting a challenging operating environment.

    Fluoguide's revenue concentration is not disclosed in the available data, but the absence of segment or geographic breakdowns suggests a lack of diversification in its revenue streams. The company's financial snapshot does not provide segment-specific data, making it difficult to assess the contribution of different product lines or geographic regions to overall performance.

    The company's growth trajectory is uncertain, with no revenue reported in the latest financial period and a net loss of 7.52 million DKK. Analysts have set a mean price target of 74.00 DKK, but the lack of revenue and negative earnings suggest a high degree of uncertainty in future performance. The absence of revenue growth in the latest period indicates a need for significant operational or strategic changes to drive future growth.

    Risk factors include medium liquidity risk and a negative net cash position after subtracting total debt. The company's dilution risk is assessed as low, with no near-term pressure from share issuance or convertible debt. However, the negative operating and free cash flows suggest a potential need for external financing, which could increase dilution risk in the future.

    Recent events include the publication of the latest financial results, which show no revenue and significant losses. Analysts have provided a consistent price target of 74.00 DKK, but the lack of revenue and negative earnings suggest a cautious outlook. The company has not disclosed any recent strategic initiatives or product launches that could drive future revenue growth.

    Key takeaways
    • Fluoguide is operating at a significant loss with no revenue reported in the latest period.
    • The company's capital structure is highly leveraged, with a debt-to-equity ratio of 1.81.
    • Profitability metrics are negative, with a return on equity of -127.89%.
    • Analysts have set a consistent price target of 74.00 DKK, but the company's financial performance suggests a high degree of uncertainty.
    • The company's liquidity is assessed as medium, with a current ratio of 1.31.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Annual
    ANNUALFiled 2026-02-25
    FY 2026 · Full-year highlights

    Revenue kr 0.00; Operating income −20,5% YoY.

    Revenuekr 0.00
    Operating income-kr 39.8M−20,5 % YoY
    Net income-kr 39.5M−36,3 % YoY
    Free cash flow-kr 38.9M−32,5 % YoY
    EPS
    Operating cash flow-kr 37.0M−26,8 % YoY
    Financials
    Income statement
    Revenuekr 0.00
    Gross profit
    Operating income-kr 39.8M
    Net income-kr 39.5M
    Balance sheet
    Total assetskr 88.3M
    Total liabilitieskr 33.8M
    Total equitykr 54.5M
    Cash & equivalents
    Long-term debtkr 28.3M
    Cash flow
    Operating cash flow-kr 37.0M
    CapEx
    Free cash flow-kr 38.9M
    SBC
    Highlights
    • Revenue kr 0.00
    • Operating income −20,5% YoY
    • Net income −36,3% YoY
    • Free cash flow −32,5% YoY

    Valuation FY

    Market price
    kr30,80
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    kr5.9M
    Net cash
    -kr10.7M
    Current ratio
    1.3
    Debt / equity
    1.8
    ROA
    -36.5%
    ROE
    -1.3%
    Cash conversion
    142.0%
    CapEx / revenue
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    -2,99
    Predicted surprise
    0,00
    Beat probability
    45 %
    Analysts
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-16 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate-2,99
    Revenueno estimateno estimate0 DKK
    Operating incomeno estimateno estimate-51,5M DKK
    Full-year consensus mean (period as reported by source) · consensus in DKK. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    12-month price targetkr74,00 · Median kr74,00
    Low kr74,00High kr74,00
    Operating income · consensus-51,5M DKK
    EPS surprise
    +6,0 %
    reported vs consensus · beat

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Lowkr74,00
    Meankr74,00
    Mediankr74,00
    Highkr74,00
    Spotkr30,80
    +140.3 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    ROE-127,9 %Bottom quartile
    D/E1,81Bottom quartile
    Cash Conv1,42Above P75

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    • Return On Assets
      net_income / total_assets
    Source documents
    • Fluoguide AS Market data — financials · 2026-05-27
    • Fluoguide AS Market data — analyst estimates · 2026-05-27

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    FLUO.STCanonical
    Nasdaq Stockholm · SEK

    Intel & risk

    PredictorBeat prob45 %Surprise0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-02-25 07:10 UTCEARNINGSAnnual results — FY 2026 Revenue DKK 0.0M · Net DKK -39.5M
    2025-02-27 06:53 UTCEARNINGSAnnual results — FY 2025 Revenue DKK 0.0M · Net DKK -29.0M
    2024-02-28 08:32 UTCEARNINGSAnnual results — FY 2024 Revenue DKK 0.0M · Net DKK -38.4M
    2023-02-28 08:12 UTCEARNINGSAnnual results — FY 2023 Net DKK -27.3M
    2022-03-30 07:45 UTCEARNINGSAnnual results — FY 2022 Net DKK -23.8M
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage